TEC-话题@MedSci

#TEC#

484篇内容 | 2656人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1652418, encodeId=ff7d16524180a, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Arthritis Rheumatol：新型JAK3/TEC抑制剂PF-06651600（ritlecitinib）对中重度类风湿性关节炎的疗效和安全性, objectType=article, longId=194372, objectId=d9c31943e212, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9c31943e212, replyNumber=0, likeNumber=80, createdTime=2020-11-13, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9c31943e212, moduleTitle=Arthritis Rheumatol：新型JAK3/TEC抑制剂PF-06651600（ritlecitinib）对中重度类风湿性关节炎的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9c31943e212)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652436, encodeId=96b716524360c, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Nat Biotechnol：新型光场显微镜高速记录大脑神经元活动和血流的快速动态变化, objectType=article, longId=199477, objectId=77c71994e763, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77c71994e763, replyNumber=0, likeNumber=90, createdTime=2021-02-19, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77c71994e763, moduleTitle=Nat Biotechnol：新型光场显微镜高速记录大脑神经元活动和血流的快速动态变化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77c71994e763)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652446, encodeId=5323165244644, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Front Bioeng Biotechnol：新型植入支架可更好的防止血栓形成和支架内再狭窄, objectType=article, longId=203080, objectId=669320308088, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=669320308088, replyNumber=0, likeNumber=0, createdTime=2021-05-12, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=669320308088, moduleTitle=Front Bioeng Biotechnol：新型植入支架可更好的防止血栓形成和支架内再狭窄, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=669320308088)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652458, encodeId=60061652458d8, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=药监局已批准新冠疫苗Ⅱ期临床，BioNTech明年供应至少1亿剂, objectType=article, longId=205615, objectId=cdcb20561580, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdcb20561580, replyNumber=0, likeNumber=45, createdTime=2021-08-25, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdcb20561580, moduleTitle=药监局已批准新冠疫苗Ⅱ期临床，BioNTech明年供应至少1亿剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cdcb20561580)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652431, encodeId=9d5d1652431c3, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=FDA批准CAR-T细胞疗法Tecartus治疗复发难治套细胞淋巴瘤, objectType=article, longId=198053, objectId=701319805312, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=701319805312, replyNumber=0, likeNumber=85, createdTime=2021-01-31, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=701319805312, moduleTitle=FDA批准CAR-T细胞疗法Tecartus治疗复发难治套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=701319805312)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652422, encodeId=87911652422dd, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=提供大幅折扣后，英国NICE批准了罗氏的PD-L1单抗Tecentriq治疗三阴性乳腺癌, objectType=article, longId=195499, objectId=9c0719549995, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c0719549995, replyNumber=0, likeNumber=102, createdTime=2021-04-16, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c0719549995, moduleTitle=提供大幅折扣后，英国NICE批准了罗氏的PD-L1单抗Tecentriq治疗三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c0719549995)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652437, encodeId=9810165243ef6, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=辉瑞与BioNTech：三期临床试验规模扩大，最终结果10月底见分晓, objectType=article, longId=200679, objectId=181a2006e961, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=181a2006e961, replyNumber=0, likeNumber=75, createdTime=2021-02-24, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=181a2006e961, moduleTitle=辉瑞与BioNTech：三期临床试验规模扩大，最终结果10月底见分晓, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=181a2006e961)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652410, encodeId=3e8a16524103b, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Nat Biotech：对抗实体肿瘤，研究者发现CAR巨噬细胞新疗法！, objectType=article, longId=190814, objectId=fc0619081491, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc0619081491, replyNumber=0, likeNumber=58, createdTime=2020-03-27, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc0619081491, moduleTitle=Nat Biotech：对抗实体肿瘤，研究者发现CAR巨噬细胞新疗法！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc0619081491)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652459, encodeId=b0621652459db, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Nature Biotechnology：高血压延迟病毒清除并加剧COVID-19患者的气道炎症, objectType=article, longId=205668, objectId=4f27205668e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f27205668e2, replyNumber=0, likeNumber=94, createdTime=2021-12-02, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f27205668e2, moduleTitle=Nature Biotechnology：高血压延迟病毒清除并加剧COVID-19患者的气道炎症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f27205668e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652442, encodeId=7b73165244249, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=BioNTech/辉瑞向欧盟提交COVID-19疫苗滚动上市申请, objectType=article, longId=201861, objectId=ef3f20186143, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef3f20186143, replyNumber=0, likeNumber=63, createdTime=2021-05-18, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef3f20186143, moduleTitle=BioNTech/辉瑞向欧盟提交COVID-19疫苗滚动上市申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef3f20186143)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652462, encodeId=f473165246200, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=WCLC 2020：Datopotamab deruxtecan和Enhertu在晚期非小细胞肺癌患者中显示出有希望的临床活性, objectType=article, longId=206512, objectId=763d20651203, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=763d20651203, replyNumber=0, likeNumber=80, createdTime=2021-09-27, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=763d20651203, moduleTitle=WCLC 2020：Datopotamab deruxtecan和Enhertu在晚期非小细胞肺癌患者中显示出有希望的临床活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=763d20651203)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652438, encodeId=e97d16524389c, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=德尼培携静脉注射治疗和介入导管手术的新型导管解决方案亮相2020Medtec中国展, objectType=article, longId=201092, objectId=11c620109206, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11c620109206, replyNumber=0, likeNumber=54, createdTime=2021-08-23, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11c620109206, moduleTitle=德尼培携静脉注射治疗和介入导管手术的新型导管解决方案亮相2020Medtec中国展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11c620109206)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652433, encodeId=36fe1652433a7, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=罗氏PD-L1单抗Tecentriq联合靶向疗法：获FDA批准治疗晚期黑色素瘤, objectType=article, longId=198563, objectId=ec5d198563ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec5d198563ab, replyNumber=0, likeNumber=80, createdTime=2021-01-12, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec5d198563ab, moduleTitle=罗氏PD-L1单抗Tecentriq联合靶向疗法：获FDA批准治疗晚期黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec5d198563ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652425, encodeId=8d2c1652425a3, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Nat Biotech：定向改造肠道微生物群，可抑制动脉粥样硬化的发生, objectType=article, longId=196354, objectId=a5691963546f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5691963546f, replyNumber=0, likeNumber=71, createdTime=2021-04-26, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5691963546f, moduleTitle=Nat Biotech：定向改造肠道微生物群，可抑制动脉粥样硬化的发生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5691963546f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652457, encodeId=86fe165245ee5, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=辉瑞和BioNTech将额外向欧盟提供1亿支COVID-19疫苗（COMIRNATY）, objectType=article, longId=205039, objectId=f591205039cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f591205039cf, replyNumber=0, likeNumber=73, createdTime=2021-06-18, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f591205039cf, moduleTitle=辉瑞和BioNTech将额外向欧盟提供1亿支COVID-19疫苗（COMIRNATY）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f591205039cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652450, encodeId=6b671652450cb, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=新冠大流行转折点？辉瑞，BioNTech正式向美国FDA提交申请以批准新冠疫苗, objectType=article, longId=203593, objectId=90be20359388, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90be20359388, replyNumber=0, likeNumber=60, createdTime=2021-04-19, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90be20359388, moduleTitle=新冠大流行转折点？辉瑞，BioNTech正式向美国FDA提交申请以批准新冠疫苗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90be20359388)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652447, encodeId=a9a2165244e85, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=重大突破：辉瑞和BioNTech研发的新冠疫苗90％有效, objectType=article, longId=203207, objectId=0b4920320e19, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b4920320e19, replyNumber=0, likeNumber=69, createdTime=2021-02-01, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b4920320e19, moduleTitle=重大突破：辉瑞和BioNTech研发的新冠疫苗90％有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b4920320e19)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652449, encodeId=20351652449c0, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Nat Biotechnol ：十年监测发现，更安全基因治疗载体AAV，竟有潜在致癌性, objectType=article, longId=203590, objectId=618120359083, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=618120359083, replyNumber=0, likeNumber=75, createdTime=2021-05-31, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=618120359083, moduleTitle=Nat Biotechnol ：十年监测发现，更安全基因治疗载体AAV，竟有潜在致癌性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=618120359083)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652409, encodeId=6a341652409c7, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Stabilitech公司开发出COVID-19疫苗的口服胶囊，患者可自行服用, objectType=article, longId=190530, objectId=f56a19053001, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f56a19053001, replyNumber=0, likeNumber=82, createdTime=2021-01-04, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f56a19053001, moduleTitle=Stabilitech公司开发出COVID-19疫苗的口服胶囊，患者可自行服用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f56a19053001)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652392, encodeId=aee7165239220, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq组合显着降低黑色素瘤患者的疾病进展和死亡风险, objectType=article, longId=184877, objectId=fe901848e7f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe901848e7f2, replyNumber=0, likeNumber=67, createdTime=2020-09-11, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe901848e7f2, moduleTitle=罗氏的PD-L1单抗Tecentriq组合显着降低黑色素瘤患者的疾病进展和死亡风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe901848e7f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

TEC

2020-05-29

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Arthritis Rheumatol：新型JAK3/TEC抑制剂PF-06651600（ritlecitinib）对中重度类风湿性关节炎的疗效和安全性

2020-11-13

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Nat Biotechnol：新型光场显微镜高速记录大脑神经元活动和血流的快速动态变化

2021-02-19

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Front Bioeng Biotechnol：新型植入支架可更好的防止血栓形成和支架内再狭窄

2021-05-12

shock_melon (审核中...)

前往app查看评论内容

#TEC#

药监局已批准新冠疫苗Ⅱ期临床，BioNTech明年供应至少1亿剂

2021-08-25

shock_melon (审核中...)

前往app查看评论内容

#TEC#

FDA批准CAR-T细胞疗法Tecartus治疗复发难治套细胞淋巴瘤

2021-01-31

shock_melon (审核中...)

前往app查看评论内容

#TEC#

提供大幅折扣后，英国NICE批准了罗氏的PD-L1单抗Tecentriq治疗三阴性乳腺癌

2021-04-16

shock_melon (审核中...)

前往app查看评论内容

#TEC#

辉瑞与BioNTech：三期临床试验规模扩大，最终结果10月底见分晓

2021-02-24

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Nat Biotech：对抗实体肿瘤，研究者发现CAR巨噬细胞新疗法！

2020-03-27

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Nature Biotechnology：高血压延迟病毒清除并加剧COVID-19患者的气道炎症

2021-12-02

shock_melon (审核中...)

前往app查看评论内容

#TEC#

BioNTech/辉瑞向欧盟提交COVID-19疫苗滚动上市申请

2021-05-18

shock_melon (审核中...)

前往app查看评论内容

#TEC#

WCLC 2020：Datopotamab deruxtecan和Enhertu在晚期非小细胞肺癌患者中显示出有希望的临床活性

2021-09-27

shock_melon (审核中...)

前往app查看评论内容

#TEC#

德尼培携静脉注射治疗和介入导管手术的新型导管解决方案亮相2020Medtec中国展

2021-08-23

shock_melon (审核中...)

前往app查看评论内容

#TEC#

罗氏PD-L1单抗Tecentriq联合靶向疗法：获FDA批准治疗晚期黑色素瘤

2021-01-12

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Nat Biotech：定向改造肠道微生物群，可抑制动脉粥样硬化的发生

2021-04-26

shock_melon (审核中...)

前往app查看评论内容

#TEC#

辉瑞和BioNTech将额外向欧盟提供1亿支COVID-19疫苗（COMIRNATY）

2021-06-18

shock_melon (审核中...)

前往app查看评论内容

#TEC#

新冠大流行转折点？辉瑞，BioNTech正式向美国FDA提交申请以批准新冠疫苗

2021-04-19

shock_melon (审核中...)

前往app查看评论内容

#TEC#

重大突破：辉瑞和BioNTech研发的新冠疫苗90％有效

2021-02-01

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Nat Biotechnol ：十年监测发现，更安全基因治疗载体AAV，竟有潜在致癌性

2021-05-31

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Stabilitech公司开发出COVID-19疫苗的口服胶囊，患者可自行服用

2021-01-04

shock_melon (审核中...)

前往app查看评论内容

#TEC#

罗氏的PD-L1单抗Tecentriq组合显着降低黑色素瘤患者的疾病进展和死亡风险

2020-09-11

科室
- - 订阅+
  - 更多科室
工具
服务